DBS

AECOM joint venture to provide program management services for the Chicago Department of Water Management’s capital improvement program

Retrieved on: 
목요일, 10월 5, 2023
Professional Services, Logistics, Supply Chain Management, Mining, Minerals, Sustainability, Green Technology, Natural Resources, Engineering, Contracts, Public Transport, Utilities, Oil, Gas, Manufacturing, Coal, Alternative Energy, Energy, Trucking, Rail, Maritime, Air, Transport, Nuclear, Defense, Environment, Building Systems, Urban Planning, Landscape, Consulting, Architecture, Construction & Property, Partnership, Health, Knowledge, NYSE, Plant, DBS, Drinking water, Science and technology in Asia, Tree, DWM, ACM, Safety, City, Rehabilitation, Chicago Department of Transportation, Water purification, Renewable energy, AECOM

AECOM (NYSE: ACM), the world’s trusted infrastructure consulting firm, announced today that its AECOM-DBS joint venture with minority-owned business enterprise partner DB Sterlin (DBS) has been awarded a 3-year contract to provide program management services to the Chicago Department of Water Management (DWM).

Key Points: 
  • AECOM (NYSE: ACM), the world’s trusted infrastructure consulting firm, announced today that its AECOM-DBS joint venture with minority-owned business enterprise partner DB Sterlin (DBS) has been awarded a 3-year contract to provide program management services to the Chicago Department of Water Management (DWM).
  • In this role, AECOM-DBS will manage the capital improvement program for DWM’s facilities, which deliver nearly 750 million gallons of drinking water to residents daily.
  • Work will focus on numerous DWM assets, including improvements to its 4,300-mile water distribution system, 12 pumping stations, and two of the world’s largest water purification plants.
  • “We’re proud to build on our longstanding partnership collaborating with DBS on dozens of projects in Chicago to lead DWM’s capital improvement program,” said Beverley Stinson, chief executive of AECOM’s global Water business.

The Hackett Group Announces 2023 Digital Award Winners

Retrieved on: 
목요일, 10월 5, 2023
Technology, Finance, Consulting, Professional Services, Software, Networks, Internet, Data Management, Other Professional Services, Knowledge, Algorithm, Simon Hackett, DBS, NLU, Customer experience, Intelligence, Abstract, Automation, MTN, AI, SAP, Digital contact tracing, Digital, Operational excellence, Artificial intelligence, Runbook, Remix, Platform as a service, System, Signavio, Synthetic media, Information technology, Mining, Talent, DBS Bank, ROI, African, Infrastructure as a service, Service provider, Association of Media in Digital Awards, Online shopping, Sales, 3D printing, Video game, Mobile phone, Sanofi

The Hackett Group , Inc. (NASDAQ: HCKT) today announced the winners of its 10th Annual Digital Awards, which spotlight companies that are on the cutting edge of creating competitive advantage and delivering measurable benefits at scale using digital transformation solutions.

Key Points: 
  • The Hackett Group , Inc. (NASDAQ: HCKT) today announced the winners of its 10th Annual Digital Awards, which spotlight companies that are on the cutting edge of creating competitive advantage and delivering measurable benefits at scale using digital transformation solutions.
  • The 2023 Digital Award winners and their win categories are: Bosch Service Solutions GmbH (Contact-to-Resolution); DBS Bank Ltd (Technology Function Operations); F. Hoffmann-La Roche Ltd. (Plan-to-Source-to-Make-to-Deliver); IBM International Services Centre Slovakia (Order-to-Cash); MTN Group Global Sourcing and Supply Chain (Source-to-Purchase); and Sanofi (Talent Management).
  • According to Vin Kumar, managing partner, AI and Digital Operations practice leader at The Hackett Group®, “This year’s winners demonstrate the real progress that’s being made as automation becomes more intelligent.
  • Our 2023 Digital Award winners are building automation fabrics that generate real insights about customers, suppliers, users, employees and more, then use those insights to make better decisions.

Veralto Begins Trading as Public Company

Retrieved on: 
월요일, 10월 2, 2023
Linx, Human, Food, Drinking water, VES, Danaher, OTT, Innovation, Medicine, Water cycle, Recycling, Danaher Corporation, Water quality, DBS, Pantone, Vital, Water, XOS, Quality control, Growth, NYSE, Safety, Bottled water, Medical device, Hach

WALTHAM, Mass., Oct. 2, 2023 /PRNewswire/ -- Today marked the first day of regular way trading for Veralto (NYSE: VLTO) as it begins its new journey as a publicly traded company.

Key Points: 
  • Veralto separated from its former parent, Danaher Corporation, on September 30, 2023.
  • "At Veralto, we are driven by our purpose: Safeguarding the World's Most Vital Resources," said Jennifer L. Honeycutt, President and Chief Executive Officer of Veralto.
  • The success of the Veralto operating companies is bolstered by the organization's use of the Veralto Enterprise System (VES), a derivative of the Danaher Business System (DBS).
  • Jennifer L. Honeycutt and the Veralto Executive Team will commemorate the new public listing of the company by ringing the opening bell at the New York Stock Exchange on Monday, October 9, 2023.

INBRAIN Neuroelectronics Announces FDA Breakthrough Device Designation for Its Graphene-Based Intelligent Network Modulation Platform

Retrieved on: 
화요일, 9월 19, 2023
Neurology, FDA, Medical Devices, Health, Health Technology, BCI, Multimedia, Steel, Carbon, Biomarker, Science, DBS, BDD, Neuropsychiatric Disease and Treatment, Stanford University School of Medicine, Patient, Subthalamic nucleus, STN, Neuro, Breakthrough, Pharmaceutical industry, Medical imaging, Medical device

, a health-tech company dedicated to developing the world’s first intelligent graphene-neural platform, today announced that its Intelligent Network Modulation System has been granted Breakthrough Device Designation (BDD) from the U.S. Food & Drug Administration (FDA) as an adjunctive therapy for treating Parkinson’s disease.

Key Points: 
  • , a health-tech company dedicated to developing the world’s first intelligent graphene-neural platform, today announced that its Intelligent Network Modulation System has been granted Breakthrough Device Designation (BDD) from the U.S. Food & Drug Administration (FDA) as an adjunctive therapy for treating Parkinson’s disease.
  • The thinnest material known, yet stronger than steel, graphene’s unique combination of electrical and mechanical properties makes it ideal for neurotechnology innovation.
  • “Breakthrough device designation from the FDA signifies the potential of the INBRAIN neural platform to further improve the lives of patients with Parkinson’s disease,” said INBRAIN Neuroelectronics Clinical Affairs Head Dan Gnansia.
  • “INBRAIN’s new generation of ultrathin graphene-based high resolution interfaces and associated network platform may vastly improve the precision, efficiency and efficacy of DBS and closed-loop or adaptive modulation.

Exploring Parkinson's Disease Statistics: Market Insight, Epidemiology ,Forecast Price and Market Access ,Commercial Strategy Analysis, Drug Development & Healthcare Consulting Services by Disease landscape Insights

Retrieved on: 
목요일, 9월 14, 2023
Non-invasive ventilation, Health care, DSM-IV codes, Diverticulitis, Cerebrospinal fluid, Protein, Patient, Risk, Disease, Tremor, Genetics, Spinal cord, Gait abnormality, Genetic testing, Brain, Dopamine, Research, Approximation error, Magnetic resonance, Biomarker, Parkinson's disease, DLI, Diagnosis, Alzheimer's disease, FDA, Magnetic resonance imaging, Horizon, Safety, Exercise, Functional magnetic resonance imaging, DBS, Algorithm, Roger Hawkins (drummer), Research and development, Central nervous system, Clinical trial, Quality of life, Deep brain stimulation, Movement, MRI, L-DOPA, Scan (company), AI, Artificial intelligence, Pharmaceutical industry, Medical imaging, Medical device, Forestry, Dietary supplement

Advancements in Parkinson's Disease Diagnosis: Facilitating Patient Care

Key Points: 
  • Advancements in Parkinson's Disease Diagnosis: Facilitating Patient Care
    Parkinson's Disease can be challenging to diagnose, often leading to delayed treatment initiation.
  • However, recent advancements in diagnostic tools have empowered healthcare professionals to identify the disease more accurately and at earlier stages.
  • DiseaseLandscape Insights is at the forefront of drug insights and discovery, product launches, and clinical trial feasibility analysis in the fight against Parkinson's Disease.
  • The Parkinson's Disease Overview by healthcare consulting services provider DLI shows that it is competitive, with pharmaceutical companies vying to develop better treatments.

GIP Launched ASEAN Chapter, Vision 2026 and New WG at its 5th Plenary Meeting

Retrieved on: 
목요일, 9월 7, 2023
Chapter, BRI, ASEAN, Senior, Lord, Standard Chartered, EM, Disclosure, ISSB, World Bank, Standard, Vision, DBS, Biodiversity, HM, International Liaison Department of the Chinese Communist Party, City, Climate change, MD, Nature, FIS, PBOC, G20, GIP, BOC, Belt, Secretariat, JIN, WG, Renewable energy

BEIJING, Sept. 7, 2023 /PRNewswire/ -- The 5th Plenary Meeting of the Green Investment Principles (GIP) for the Belt and Road was successfully convened in Beijing.

Key Points: 
  • BEIJING, Sept. 7, 2023 /PRNewswire/ -- The 5th Plenary Meeting of the Green Investment Principles (GIP) for the Belt and Road was successfully convened in Beijing.
  • To reflect global trends in sustainable finance, GIP renews its medium-term strategy and announced Vision 2026/2030, which introduces the "Transition" pillar.
  • A GIP casebook was launched to demonstrate good practices in green investments along the Belt and Road and implementation of GIP principles.
  • In recognition of exceptional implementation of GIP principles and product innovation by its members, the Secretariat announced winners of the 2023 GIP Awards.

CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients

Retrieved on: 
금요일, 9월 1, 2023
Gaucher's disease, GBA1, Diagnosis, Prognosis, GD, DBS, Patient, Collection, Physician, CNTG, Enzyme replacement therapy, Medical imaging, Gaucher

“Over the past decade, we have leveraged all our multiomic technological know-how to establish and confirm lyso-Gb1 as the best biomarker for Gaucher disease,” said Professor Peter Bauer, CENTOGENE’s Chief Medical and Genomic Officer.

Key Points: 
  • “Over the past decade, we have leveraged all our multiomic technological know-how to establish and confirm lyso-Gb1 as the best biomarker for Gaucher disease,” said Professor Peter Bauer, CENTOGENE’s Chief Medical and Genomic Officer.
  • “This landmark study further advances our understanding of Gaucher disease patients – demonstrating a significant correlation between lyso-Gb1 levels and disease severity.
  • The results of the study revealed a highly significant correlation between lyso-Gb1 and disease severity in all Gaucher patients, including those with novel rare GBA1 variants.
  • “The progressive increase in lyso-Gb1 levels in untreated Gaucher patients suggests that these patients could benefit from treatment, such as enzyme replacement therapy.

Danaher Releases 2023 Sustainability Report

Retrieved on: 
수요일, 8월 16, 2023
Sustainability reporting, Danaher, Woman, DHR, TCFD, Danaher Corporation, DBS, Task force, The Company, Environment, NYSE, Female, Task Force on Climate Related Financial Disclosures, Mining, Renewable energy

WASHINGTON, Aug. 16, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), the global science and technology innovator, today published its 2023 Sustainability Report which conveys the depth and scope of Danaher's sustainability program and highlights important milestones the Company achieved during the past year.

Key Points: 
  • WASHINGTON, Aug. 16, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), the global science and technology innovator, today published its 2023 Sustainability Report which conveys the depth and scope of Danaher's sustainability program and highlights important milestones the Company achieved during the past year.
  • At the heart of everything we do at Danaher is our commitment to continuous improvement, and our sustainability program exemplifies this commitment," said Rainer Blair, President and Chief Executive Officer.
  • This year's report details several key accomplishments across Danaher's sustainability strategic pillars:
    Danaher updated its Danaher Business System (DBS) product development tools to prompt consideration of our customers' sustainability needs at key junctures in the product design, development and launch processes.
  • To learn more about Danaher's sustainability initiatives and to read or download the 2023 sustainability report, please visit www.danaher.com/sustainability .

Enspire DBS Therapy Announces the Publication of EDEN, an Early Feasibility Trial of Deep Brain Stimulation (DBS) plus Rehab for Stroke Patients, in Nature Medicine

Retrieved on: 
화요일, 8월 15, 2023
Cleveland Clinic, Neurostimulation, Stroke, Research, Dentate nucleus, DBS, Patient, EDEN, IDE, FDA, Disability studies, Safety, Pharmaceutical industry, Nature Medicine

The EDEN study was designed to evaluate whether DBS plus rehabilitation therapy (DBS+Rehab) would improve motor function in patients post Ischemic Stroke more effectively than rehab alone.

Key Points: 
  • The EDEN study was designed to evaluate whether DBS plus rehabilitation therapy (DBS+Rehab) would improve motor function in patients post Ischemic Stroke more effectively than rehab alone.
  • The study demonstrated that the majority of participants (9 out of 12) showed the most significant improvements in both motor impairment and function during the combination therapy, DBS+Rehab.
  • Importantly, participants with at least minimal preservation of distal motor function at enrollment showed clinically significant gains.
  • Dr. Machado patented the DBS method in stroke recovery to which Enspire has an exclusive license.

UT Health Science Center San Antonio recognized as Parkinson's Foundation Comprehensive Care Center

Retrieved on: 
화요일, 8월 1, 2023
Workforce, Huntington's disease, Deep brain stimulation, Hallucination, University, Center of excellence, Tic, Parkinson's Foundation, University of Texas System, University of Texas Health Science Center at San Antonio, Senior counsel, DSM-IV codes, Therapy, Health, Parkinson's disease dementia, Quality of life, UT Health San Antonio Cancer Center, Research, Brain, Neurology, Department of Neurology, Xuanwu hospital, Dystonia, Bone, Movement, Teaching hospital, Essential tremor, Pain, Social, DBS, Electrode, Parkinson's disease, Neurosurgery, MD, Patient, SAN, Person-centered therapy, Rush Alzheimer's Disease Center, Long School, Long School of Medicine, Movement disorder, Bleeding, Memory, Skin, Disease, Pharmaceutical industry, Nursing, Veterinary medicine, Dentistry, Central Texas

SAN ANTONIO, Aug. 1, 2023 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been designated a Parkinson's Foundation Comprehensive Care Center, the first of its kind in the state of Texas.

Key Points: 
  • Advanced multidisciplinary care for Parkinson's disease is available at The University of Texas Health Science Center at San Antonio, which this summer was named a Parkinson's Foundation Comprehensive Care Center.
  • SAN ANTONIO, Aug. 1, 2023 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been designated a Parkinson's Foundation Comprehensive Care Center, the first of its kind in the state of Texas.
  • The UT Health San Antonio Movement Disorders Center is also recognized as a Huntington's Disease Center of Excellence and provides comprehensive care for patients with Huntington's disease.
  • The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver for San Antonio's $44.1 billion health care and biosciences sector, is the largest academic research institution in South Texas with an annual research portfolio of more than $360 million.